top of page

Medication Policy

Date Completed: (14/07/2025)
Completed By: Neuroshine
ICO Registration Number: [Insert, if registered]

1. Purpose

This Medication Policy sets out Neuroshine’s approach to the safe, ethical, and effective prescribing and management of medication for individuals with ADHD and related conditions. Our aim is to ensure that all prescribing follows UK regulatory requirements and prioritises client safety and wellbeing.

2. Scope

  • This policy applies to:

  • All prescribing clinicians employed or contracted by Neuroshine (psychiatrists, doctors, nurse prescribers)

  • Administrative staff involved in prescription processing

  • Clients receiving medical services through Neuroshine

3. Prescribing Principles

1. Qualified Prescribers Only

  • Medication will only be prescribed by appropriately qualified and registered healthcare professionals (e.g., GMC-registered doctors, NMC-registered nurse prescribers).

2. Evidence-Based Practice

  • Prescribing will be based on NICE guidelines and other relevant professional standards.

3.​ Individualised Care

  • Medication will be tailored to the client’s needs, based on assessment, medical history, and ongoing review.

4. Informed Consent

  • Clients will receive clear information about the purpose, benefits, risks, and side effects of medication before treatment begins.

4. Prescribing and Monitoring Process

  • Assessment: A thorough medical assessment will be conducted prior to prescribing.

  • Initiation: Prescriptions will be issued following clinical decision-making and client consent.

  • Monitoring: Regular follow-up appointments will be scheduled to review effectiveness, side effects, and adherence.

  • Adjustments: Dosage or medication changes will be made only after clinical evaluation.

  • Shared Care: Where appropriate, prescribing may transition to a client’s GP under a shared care agreement.

5. Storage, Supply, and Handling

  • Controlled Drugs (CDs): If applicable, Neuroshine complies with the Misuse of Drugs Regulations 2001.

  • Electronic Prescriptions: Neuroshine uses and electronic prescribing systems (EPS) to reduce risk of misuse.

  • Record Keeping: Accurate records will be maintained for all prescriptions and medication-related communications.

6. Safeguarding and Safety

  • Misuse Prevention: Prescribers will remain alert to risks of diversion, misuse, or dependency.

  • Safeguarding: Concerns regarding medication misuse or risk of harm will be escalated in line with the Neuroshine Safeguarding Policy.

  • Adverse Reactions: Clients are advised to report side effects immediately; serious adverse events will be reported through the MHRA Yellow Card Scheme.

7. Client Responsibilities

Clients are expected to:

  • Use medication only as prescribed

  • Report side effects or concerns promptly

  • Store medication safely and securely

  • Not share medication with others

  • Attend scheduled review appointments

8. Training and Compliance

  • Prescribers must maintain professional registration and undertake regular CPD.

  • Staff handling prescriptions must be trained in confidentiality, safeguarding, and data protection.

  • Neuroshine will review prescribing practices regularly as part of clinical governance.

9. Review of Policy
This policy will be reviewed annually or sooner if required by updates in legislation, clinical guidance, or organisational needs.

 
10. Contact
For questions about this policy, contact:
Neuroshine Clinical Governance Team
Email: support@neuroshine.co.uk
Phone: [Insert Contact Number]

bottom of page